Santen, Arctic Vision sign deal for ARVN001 to treat UME

Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic macular oedema.

Nov 9, 2024 - 06:00

Santen, Arctic Vision sign deal for ARVN001 to treat UME

Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic macular oedema.

Read the original article

Tags:

Previous Article

Sonnet BioTherapeutics secures US patent covering two drug candidates

Private equity deals in pharmaceutical in Canada remained flat in Q3 2024

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Apollo Therapeutics secures $226.5m to advance pipeline programmes

Apollo Therapeutics secures $226.5m to advance pipeline...

Sep 7, 2023

Trump triumphs but impact on healthcare industry remains unclear

Trump triumphs but impact on healthcare industry remain...

Nov 7, 2024

The potential of AI in pharma R&D

The potential of AI in pharma R&D

Jun 15, 2023